Green and Sensitive Investigation for Estimation of Anticancer Medication in Raw Material and Dosage Form: Greenness Assessment Consideration.

Larotrectinib or VITRAKVI is a first-generation pan-tropomyosin-related kinase (TRK) inhibitor. It is a highly selective, tumor-agnostic agent which has been approved in both adult and pediatric patients. Three different analytical methods for estimation of such important drug were developed.